# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announces $0.5 price target.
CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(6.72) per share. This is a 87.04 percent increase over losses ...
Cash Position At $1.5M With Additional $12.4M Raised Post-June 30; Sufficient Funds Through Q1 2025, Final Berubicin Trial Data...
CNS Pharmaceuticals entered into a exclusive license agreement with Cortice Biosciences.